AI-generated analysis. Always verify with the original filing.
Allarity Therapeutics, Inc. entered into a note purchase agreement with Streeterville Capital, LLC on March 2, 2026, issuing a $10.93M A-1 Note (OID $0.9M) for $10M cash and a $10M secured B Note backed by $10M deposit at Lakeside Bank. The notes mature in 18 months with interest rates of 9% and 5%, secured by subsidiary guaranties and pledges, imposing restrictive covenants.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of thi
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 4.1 Secured Promissory Note A-1, dated March 2, 2026. 4.2 Secured Promissory Note B,
Material Agreement
Debt / Financing